Pemetrexed disodium is a tumor drug successfully developed by Eli Lilly Pemetrexed disodium is a multi-target antifolate preparation with pyrrolidine pyrimidine group in structure. It is a dual inhibitor of nucleotide synthase enzyme / dihydrofolate reductase. It can inhibit cell replication by destroying the normal folate dependent metabolism process in cells, and block three different enzyme targets that are crucial to the survival of cancer cells at the same time, So as to inhibit the growth of tumor.